KURA

Kura Oncology, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.65
52-Week Range: $7.36 – $13.90
Market Cap: $947.43M
P/E (TTM): —
EPS (TTM): -3.37
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 19.58
PEG Ratio: —
Return on Equity: -167.71%
Return on Assets: -31.30%
Gross Margin: -236.72%
Operating Margin: -349.77%
Profit Margin: 0.00%
Current Ratio: 4.73
Debt/Equity: 0.50
Total Debt: $24.45M
Free Cash Flow: $-165.88M
Revenue Growth: 36.50%
Earnings Growth: —
Enterprise Value: $452.86M

KURA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$53.88M	$67.48M
Cost of Revenue	—	$0.00	$0.00	$57.00K
Gross Profit	—	$0.00	$53.88M	$67.42M
Research & Development	$92.81M	$115.23M	$169.97M	$251.07M
Selling, General & Admin	$47.05M	$50.57M	$77.11M	$119.98M
Operating Expenses	$139.87M	$165.80M	$247.08M	$371.06M
Operating Income	-$139.87M	-$165.80M	-$193.19M	-$303.63M
EBITDA	-$134.85M	-$150.23M	-$169.50M	-$275.82M
Pretax Income	-$135.84M	-$152.63M	-$171.97M	-$278.37M
Income Tax	$0.00	$0.00	$2.02M	$297.00K
Net Income	-$135.84M	-$152.63M	-$173.98M	-$278.67M
Diluted EPS	-2.03	-2.08	-2.02	-3.18
Diluted Shares	66.99M	73.23M	86.16M	87.68M

KURA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$51.80M	$37.32M	$224.46M	$149.10M
Receivables	—	—	$2.06M	$8.80M
Inventory	—	—	$0.00	$413.00K
Current Assets	$446.43M	$432.48M	$744.83M	$708.66M
Total Assets	$456.31M	$448.94M	$760.16M	$738.36M
Current Liabilities	$24.06M	$35.26M	$78.71M	$116.97M
Long-Term Debt	$9.16M	$9.33M	$6.92M	$9.71M
Total Debt	$14.02M	$17.20M	$16.59M	$20.46M
Total Liabilities	$36.03M	$51.66M	$346.52M	$564.23M
Retained Earnings	-$568.81M	-$721.44M	-$895.42M	-$1.17B
Shareholders' Equity	$420.28M	$397.27M	$413.64M	$174.13M
Working Capital	$422.37M	$397.22M	$666.12M	$591.69M

KURA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$110.06M	-$124.82M	$134.32M	-$64.06M
Capital Expenditure	-$626.00K	-$168.00K	-$472.00K	-$6.64M
Free Cash Flow	-$110.69M	-$124.99M	$133.84M	-$70.70M
Depreciation & Amortisation	$759.00K	$849.00K	$848.00K	$1.03M
Stock-Based Compensation	$26.32M	$28.08M	$33.90M	$37.11M
Investing Cash Flow	$32.63M	$15.56M	-$101.59M	-$13.10M
Financing Cash Flow	$38.56M	$94.78M	$154.42M	$1.79M
Net Change in Cash	-$38.87M	-$14.48M	$187.14M	-$75.36M

KURA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$14.11M	$15.29M	$20.75M	$17.34M	$18.27M	$20.87M
Cost of Revenue	$0.00	$0.00	—	—	$262.00K	$243.00K
Gross Profit	$14.11M	$15.29M	—	—	$18.00M	$20.63M
Research & Development	$55.97M	$62.78M	$67.91M	$64.41M	$65.26M	$61.89M
Selling, General & Admin	$22.84M	$25.17M	$32.84M	$39.14M	$31.55M	$31.75M
Operating Expenses	$78.81M	$87.95M	$100.75M	$103.55M	$96.82M	$93.64M
Operating Income	-$64.70M	-$72.67M	-$80.00M	-$86.27M	-$78.81M	-$73.01M
EBITDA	-$56.58M	-$65.51M	-$73.56M	-$80.18M	-$72.63M	-$67.61M
Pretax Income	-$57.20M	-$66.12M	-$74.12M	-$80.93M	-$73.33M	-$68.32M
Income Tax	$226.00K	$0.00	$0.00	$71.00K	$8.00K	$5.00K
Net Income	-$57.43M	-$66.12M	-$74.12M	-$81.00M	-$73.33M	-$68.33M
Diluted EPS	-0.66	-0.75	-0.85	-0.92	-0.83	-0.77
Diluted Shares	87.42M	87.59M	87.64M	88.05M	88.61M	88.86M

KURA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$51.27M	$81.95M	$95.29M	$149.10M	$39.08M	$70.24M
Receivables	$48.75M	$4.57M	$35.94M	$8.80M	$9.35M	$9.45M
Inventory	—	—	—	$413.00K	$843.00K	$2.48M
Current Assets	$724.20M	$660.08M	$620.66M	$708.66M	$623.78M	$559.44M
Total Assets	$743.76M	$682.42M	$649.38M	$738.36M	$652.55M	$587.79M
Current Liabilities	$89.77M	$107.17M	$121.30M	$116.97M	$101.50M	$118.19M
Long-Term Debt	$7.65M	$6.51M	$5.34M	$9.71M	$9.75M	$5.57M
Total Debt	$19.35M	$19.47M	$19.47M	$20.46M	$24.27M	$24.45M
Total Liabilities	$379.36M	$376.94M	$406.84M	$564.23M	$544.67M	$539.36M
Retained Earnings	-$952.85M	-$1.02B	-$1.09B	-$1.17B	-$1.25B	-$1.32B
Shareholders' Equity	$364.41M	$305.49M	$242.54M	$174.13M	$107.88M	$48.43M
Working Capital	$634.43M	$552.90M	$499.36M	$591.69M	$522.29M	$441.25M

KURA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$71.93M	-$28.78M	-$80.63M	$117.27M	-$85.85M	-$62.55M
Capital Expenditure	-$292.00K	-$1.46M	-$2.57M	-$2.32M	-$128.00K	-$656.00K
Free Cash Flow	-$72.22M	-$30.23M	-$83.19M	$114.95M	-$85.98M	-$63.20M
Depreciation & Amortisation	$241.00K	$224.00K	$164.00K	$403.00K	$355.00K	$369.00K
Stock-Based Compensation	$7.84M	$6.95M	$10.96M	$11.35M	$8.42M	$8.21M
Investing Cash Flow	-$101.41M	$58.94M	$93.97M	-$64.60M	-$24.23M	$92.21M
Financing Cash Flow	$143.00K	$515.00K	$0.00	$1.14M	$69.00K	$1.50M
Net Change in Cash	-$173.19M	$30.68M	$13.34M	$53.81M	-$110.02M	$31.16M

Market Snapshot

About

Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for cancer treatment. The company's lead candidates include menin inhibitors for acute leukemias and farnesyl transferase inhibitors for solid tumors with specific genetic mutations. Kura focuses on genetically defined patient populations where targeted therapies can provide significant clinical benefit.